With Bayer's new launches in infancy, Eylea and Xarelto still rule its pharma...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 01, 2022 at 10:12: PM
via Bayer is gradually shifting its pharma focus to a group of new blockbuster candidates and novel platforms. But before those drugs realize their potential, eye med Eylea and blood thinner Xarelto remain the pillars.

article source
 

<



Similar threads

cafead
Navigating the AI &#039;hype cycle&#039;: Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing
Replies
0
Views
7
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ESMO: Bayer hopes to expand Nubeqa&#039;s prostate cancer reach with chemo-free regimen
Replies
0
Views
5
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
New data reveal how Bayer&#039;s asundexian failed to prevent strokes, imperiling $5.5B blockbuster hopes
Replies
0
Views
8
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
&#039;We are firing on all cylinders&#039;: Bayer pharma BD chief says group overhaul not slowing dealmaking
Replies
0
Views
29
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Bayer&#039;s finerenone clears key heart failure trial
Replies
0
Views
8
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote